Dual therapy based on raltegravir and nevirapine has been recently proposed as a possible switching strategy in selected patients, due to attractive tolerability and safety profile. We recently reported the pharmacokinetic compatibility of these drugs when administered twice-daily, but data on efficacy and safety of this combination in the clinical setting are scarce.
Efficacy and safety of Nevirapine plus raltegravir as dual regimen in the clinical setting / C., Montrucchio; A., Calcagno; A., Capetti; Guaraldi, Giovanni; G., Cenderello; L., Calza; M., Lanzafame; L., Marinaro; M. C., Tettoni; L., Trentini; G., Di Perri; S., Bonora. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - STAMPA. - 36 (suppl 1):(2013), pp. 15-15. (Intervento presentato al convegno Italian Conference on AIDS and Retrovirus tenutosi a Torino nel 12-14 May 2013).
Efficacy and safety of Nevirapine plus raltegravir as dual regimen in the clinical setting
GUARALDI, Giovanni;
2013
Abstract
Dual therapy based on raltegravir and nevirapine has been recently proposed as a possible switching strategy in selected patients, due to attractive tolerability and safety profile. We recently reported the pharmacokinetic compatibility of these drugs when administered twice-daily, but data on efficacy and safety of this combination in the clinical setting are scarce.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
